Drew C A, Johnston G A, Kerr D I, Ong J
Department of Pharmacology, University of Sydney, NSW, Australia.
Neurosci Lett. 1990 May 18;113(1):107-10. doi: 10.1016/0304-3940(90)90503-2.
The inhibition of the binding of the GABAB agonist 3H-baclofen to rat cerebellar membranes by some sulfonic and phosphonic acid analogues of GABA has been studied. These analogues have been shown to act as GABAB antagonists in the rat cortical wedge and the guinea-pig isolated ileum preparations. The order of potency of phaclofen (IC50 118 microM), 2-hydroxysaclofen (IC50 5.1 microM) and saclofen (IC50 7.8 microM) as inhibitors of 3H-baclofen binding was similar to the order of potency of these compounds as GABAB antagonists, whereas 3-aminopropylphosphonic acid (IC50 1.5 microM) and 4-aminobutyl-phosphonic acid (IC50 3.9 microM) were much more potent than anticipated from their relatively weak GABAB antagonist actions. These results indicate that inhibition of 3H-baclofen binding to rat cerebellar membranes does not reflect antagonist activity at GABAB receptors seen in the rat cortical wedge preparation or the guinea-pig isolated ileum preparation. This may indicate a heterogeneity of GABAB binding and receptor sites.
已经研究了一些γ-氨基丁酸(GABA)的磺酸和膦酸类似物对GABAB激动剂[3H]-(-)-巴氯芬与大鼠小脑膜结合的抑制作用。这些类似物已被证明在大鼠皮质楔形物和豚鼠离体回肠制备物中作为GABAB拮抗剂起作用。作为[3H]-(-)-巴氯芬结合抑制剂的法氯芬(IC50 118 microM)、2-羟基舒氯芬(IC50 5.1 microM)和舒氯芬(IC50 7.8 microM)的效力顺序与这些化合物作为GABAB拮抗剂的效力顺序相似,而3-氨基丙基膦酸(IC50 1.5 microM)和4-氨基丁基膦酸(IC50 3.9 microM)比根据其相对较弱的GABAB拮抗剂作用预期的效力要强得多。这些结果表明,抑制[3H]-(-)-巴氯芬与大鼠小脑膜的结合并不能反映在大鼠皮质楔形物制备物或豚鼠离体回肠制备物中所见的GABAB受体拮抗剂活性。这可能表明GABAB结合和受体位点存在异质性。